Article
A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607).
Cancer - 15 Jul 2017
Kalinsky Kevin, Lee Sandra, Rubin Krista M, Lawrence Donald P, Iafrarte Anthony J, Borger Darell R, Margolin Kim A, Leitao Mario M, Tarhini Ahmad A, Koon Henry B, Pecora Andrew L, Jaslowski Anthony J, Cohen Gary I, Kuzel Timothy M, Lao Christopher D, Kirkwood John M
Abstract excerpt
BACKGROUND: KIT-directed tyrosine kinase inhibitors such as imatinib have demonstrated benefits in KIT-mutant (KIT+) mucosal, acral, vulvovaginal, and chronically sun-damaged (CSD) melanoma. Dasatinib has superior preclinical activity in comparison with other tyrosine kinase inhibitors against cells with the most common KIT mutation, exon 11L576P . The ECOG-ACRIN E2607 trial assessed dasatinib in patients with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.